Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

454 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Second- or third-line treatment with erlotinib in EGFR wild-type non-small cell lung cancer: Real-life data].
Debieuvre D, Moreau L, Coudert M, Locher C, Asselain B, Coëtmeur D, Dayen C, Goupil F, Martin F, Brun P, De Faverges G, Hauss PA, Gally S, Ben Hadj Yahia B, Grivaux M. Debieuvre D, et al. Among authors: moreau l. Rev Mal Respir. 2019 Jun;36(6):649-663. doi: 10.1016/j.rmr.2019.03.010. Epub 2019 Jun 14. Rev Mal Respir. 2019. PMID: 31204231 French.
[Screening, prevention, and tobacco].
Haller MA, Moreau L. Haller MA, et al. Among authors: moreau l. Rev Pneumol Clin. 2000 Dec;Suppl 3:4-6. Rev Pneumol Clin. 2000. PMID: 11280979 French. No abstract available.
Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study.
Payen T, Trédaniel J, Moreau L, Larivé S, Le Treut J, Nocent C, Hominal S, Grangeon V, Bizec JL, Molinier O, Debieuvre D. Payen T, et al. Among authors: moreau l. Respir Med Res. 2021 Nov;80:100795. doi: 10.1016/j.resmer.2020.100795. Epub 2020 Nov 1. Respir Med Res. 2021. PMID: 34242973
Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study.
Couraud S, Barlesi F, Fontaine-Deraluelle C, Debieuvre D, Merlio JP, Moreau L, Beau-Faller M, Veillon R, Mosser J, Al Freijat F, Bringuier PP, Léna H, Ouafik L, Westeel V, Morel A, Audigier-Valette C, Missy P, Langlais A, Morin F, Souquet PJ, Planchard D; Biomarkers France Contributors. Couraud S, et al. Among authors: moreau l. Eur J Cancer. 2019 Jul;116:86-97. doi: 10.1016/j.ejca.2019.04.016. Epub 2019 Jun 8. Eur J Cancer. 2019. PMID: 31181537
Lung cancer trends and tumor characteristic changes over 20 years (2000-2020): Results of three French consecutive nationwide prospective cohorts' studies.
Debieuvre D, Molinier O, Falchero L, Locher C, Templement-Grangerat D, Meyer N, Morel H, Duval Y, Asselain B, Letierce A, Trédaniel J, Auliac JB, Bylicki O, Moreau L, Fore M, Corre R, Couraud S, Cortot A; Study Group KBP-2020-CPHG; KBP-2020-CPHG. Debieuvre D, et al. Among authors: moreau l. Lancet Reg Health Eur. 2022 Aug 29;22:100492. doi: 10.1016/j.lanepe.2022.100492. eCollection 2022 Nov. Lancet Reg Health Eur. 2022. PMID: 36108315 Free PMC article.
[Summary of the congress].
Benichou M, Coëtmeur D, Haller MA, Moreau L. Benichou M, et al. Among authors: moreau l. Rev Pneumol Clin. 2000 Dec;Suppl 3:26-9. Rev Pneumol Clin. 2000. PMID: 11280976 French. No abstract available.
454 results